Table 3.
Analysis of gut microbiota in coronavirus disease 2019 patients in different cohorts
SI. No.
|
Cohort composition
|
No of Patients
|
Demographics of the study populations
|
Country
|
Significant gut microbiota found
|
Study conclusion
|
Reference
|
1 | A pilot study with 15 healthy individuals (controls) and 15 patients with COVID-19 | 15 | Study performed with hospitalised patients (median age 55 years), Chinese ethnicity and comorbidities were reported | Hong Kong | Abundance of Clostridium hathewayi, Clostridium ramosum, Coprobacillus, which are correlated with COVID-19 severity | Change in the fecal microbiome of COVID-19 patients during hospitalization, compared to healthy individuals (controls) | [48] |
2 | The two-hospitals cohort, serial stool samples collected from 27 COVID-19 patients among 100 | 27 | Adults hospitalised Chinese patients, comorbidities were noted | Hong Kong | Faecalibacterium prausnitzii, Eubacteriumrectale and bifidobacteria | Gut microbiome involved in COVID-19 severity | [38] |
3 | United States cohort (majority African American) | 50 | Studied patients (mean age 62.3 years) were hospitalised with comorbidities, American ethnicity | United States | Some of the significant genera (Corynebacterium Peptoniphilus, Campylobacter, etc.) | No significant associations found between the composition microbiome and disease severity from COVID-19 patient gut microbiota | [50] |
4 | The study used 53 COVID-19 patients and 76 healthy individuals. 81 fecal samples collected during hospitalization | 53 | Adults Chinase hospitalised patients, no such comorbidities were noted | China | Elevated gut microbes such as Rothia mucilaginosa, Granulicatella spp, etc. | COVID-19 infection linked with change of the microbiome in COVID-19 patients | [137] |
5 | 15 patients Cohort | 15 | Study performed adults hospitalised patients with comorbidities, Chinese ethnicity | Hong Kong | Elevated bacterial species Collinsella tanakaei, Collinsella aerofaciens, Morganella morganii, Streptococcus infantis | The study found fecal viral (SARS-CoV-2) activity | [54] |
6 | Two-hospital cohort with a total of 100 patients. Stool samples collected from 27 patients | 27 | Hospitalised adults patients were from China, comorbidities were noted | Hong Kong | Several gut microbiota such as Faecalibacterium prausnitzii, Eubacterium rectale, and bifidobacteria | Gut microbiota associated disease severity and inflammation in COVID-19 patients | [38] |
7 | 98 COVID-19 patients (3 asymptomatic, 34 moderate, 53 mild, 3 critical, 5 severe), serial fecal samples collected from 37 COVID-19 patients | 37 | Adults (mean age 37 years) patients, hospitalised condition from Chinese ethnicity, comorbidities were reported | Hong Kong | A total of 10 virus species in fecal matter (9 DNA virus species and 1 RNA virus, pepper chlorotic spot virus) | Analysis of gut virome (RNA and DNA virome) in COVID-19 patients | [47] |
8 | Study of fecal samples from 30 COVID-19 patients | 30 | Patients (mean age 46 years) were hospitalised from Chinese groups, comorbidities were noted | Hong Kong | Increased proportions of fungal pathogens (Candida albicans, Candida auris, Aspergillus flavus, Aspergillus niger) in fecal samples | Analysis of fecal fungal microbiome of COVID-19 patients | [48] |
COVID-19: Coronavirus disease 2019.